Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 36476-87-6 | MDL No. : | MFCD01566539 |
Formula : | C17H17NO2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BRSCYENHLCPOAU-UHFFFAOYSA-N |
M.W : | 267.32 g/mol | Pubchem ID : | 2735440 |
Synonyms : |
|
Num. heavy atoms : | 20 |
Num. arom. heavy atoms : | 12 |
Fraction Csp3 : | 0.24 |
Num. rotatable bonds : | 4 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 81.59 |
TPSA : | 40.54 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.59 cm/s |
Log Po/w (iLOGP) : | 2.27 |
Log Po/w (XLOGP3) : | 0.48 |
Log Po/w (WLOGP) : | 2.09 |
Log Po/w (MLOGP) : | 2.62 |
Log Po/w (SILICOS-IT) : | 2.67 |
Consensus Log Po/w : | 2.03 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.98 |
Solubility : | 2.8 mg/ml ; 0.0105 mol/l |
Class : | Very soluble |
Log S (Ali) : | -0.9 |
Solubility : | 33.6 mg/ml ; 0.126 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -4.27 |
Solubility : | 0.0143 mg/ml ; 0.0000533 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 1.64 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P301+P312-P302+P352-P304+P340-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
80.8% | With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 20.5 h; | Potassium carbonate (6.53 g) and iodomethane (0.976 ml) were added to a solution of 1-benzhydrylazetidine-3-carboxylic acid (4.20 g) in N,N-dimethylformamide (45 ml), followed by stirring at room temperature for 20.5 hours. The reaction mixture was poured into ice water, and extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate. The solvent was distilled off, and the residue was purified by silica gel column chromatography (eluent; heptane:ethyl acetate=5:1, then 3:1). The fractions containing the target compound were concentrated to give the title compound (3.57 g, 80.8percent) as yellow crystals.1H-NMR Spectrum (CDCl3) δ (ppm): 3.26 (2H, m), 3.31 (1H, m), 3.44 (2H, m), 3.69 (3H, s), 4.38 (1H, s), 7.16-7.20 (2H, m), 7.25-7.28 (4H, m), 7.39-7.41 (4H, m).ESI-MS (m/z): 282[M+H]+. |
80.8% | With potassium carbonate In N,N-dimethyl-formamide at 20℃; for 20.5 h; | (Production Example 84) Methyl 1-benzhydrylazetidine-3-carboxylate A solution of 1-benzhydrylazetidine-3-carboxylic acid (4.20 g) in N,N-dimethylformamide (45 ml) were added potassium carbonate (6.53 g) and iodomethane (0.976 ml), followed by stirring at room temperature for 20.5 hr. The reaction mixture was poured into ice water, and extracted with ethyl acetate. The organic layer was washed with brine, and dried over anhydrous sodium sulfate. The solvent was removed, and the residue was purified by silica gel column chromatography (eluent; heptane:ethyl acetate = 5:1, then 3:1). Fractions containing the target compound were concentrated to provide the titled compound as yellow crystals (3.57 g, 80.8 percent). 1H-NMR Spectrum (CDCl3) δ (ppm): 3.26 (2H, m), 3.31 (1H, m), 3.44 (2H, m), 3.69 (3H, s), 4.38 (1H, s), 7.16-7.20 (2H, m), 7.25-7.28 (4H, m), 7.39-7.41 (4H, m). ESI-MS (m/z): 282 [M+H]+. |
[ 53871-06-0 ]
Methyl 1-benzhydrylazetidine-3-carboxylate
Similarity: 0.90
[ 570423-68-6 ]
1-(4-Nonylbenzyl)azetidine-3-carboxylic acid
Similarity: 0.88
[ 94985-27-0 ]
1-Benzylazetidine-3-carboxylic acid
Similarity: 0.87
[ 887591-82-4 ]
Ethyl 1-benzhydrylazetidine-3-carboxylate
Similarity: 0.87
[ 72351-37-2 ]
1-Benzhydrylazetidine-3-carbaldehyde
Similarity: 0.85
[ 570423-68-6 ]
1-(4-Nonylbenzyl)azetidine-3-carboxylic acid
Similarity: 0.88
[ 94985-27-0 ]
1-Benzylazetidine-3-carboxylic acid
Similarity: 0.87
[ 106014-87-3 ]
1-Benzylazetidine-3,3-dicarboxylic acid
Similarity: 0.84
[ 889952-36-7 ]
1-(1-Benzylpiperidin-4-yl)azetidine-3-carboxylic acid
Similarity: 0.83
[ 53871-06-0 ]
Methyl 1-benzhydrylazetidine-3-carboxylate
Similarity: 0.90
[ 570423-68-6 ]
1-(4-Nonylbenzyl)azetidine-3-carboxylic acid
Similarity: 0.88
[ 94985-27-0 ]
1-Benzylazetidine-3-carboxylic acid
Similarity: 0.87
[ 887591-82-4 ]
Ethyl 1-benzhydrylazetidine-3-carboxylate
Similarity: 0.87
[ 72351-37-2 ]
1-Benzhydrylazetidine-3-carbaldehyde
Similarity: 0.85